GlassScriptPhysician profile
Mukundini B Mehta
NPI 1154303584
$820.33
in general payments reported to CMS, 2019-2025
13 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $153 · 2021: $88.38 · 2022: $26.67 · 2023: $97.51 · 2024: $14.35 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $189.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $184.62 | 2019-2021 | |
| Exact Sciences Corporation | $70.36 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $66.15 | 2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $59.33 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Lupin INC. | $58.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.91 | 2021 | |
| Amgen INC. | $31.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.73 | 2023 | Eliquis |
| Sanofi Pasteur INC. | $20.60 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.35 | 2024 | Farxiga |
| Allergan, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukundini Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.